Prevalence and clinical impact of hepatic steatosis on autoimmune liver disease: A systematic review and meta-analysis
Rattachement africain : sg, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: The clinical impact of hepatic steatosis (HS) among patients with autoimmune liver disease (AILD) remains unclear. We aim to determine the prevalence of HS and its clinical impact on treatment response and outcomes in patients with AILD. METHODS: We systematically searched 3 electronic databases until 17 December 2025, including all studies that reported the prevalence, clinical impact, and treatment response of AILD patients with concomitant HS. The temporal trend of HS prevalence was analyzed using a quasi-Poisson regression model, with annual percent changes (APC, %) calculated. RESULTS: Overall, 44 studies, comprising 19,898 patients with autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) were included. The pooled prevalence of HS in patients with AIH, PBC, and PSC was 27.3%, 32.9%, and 21.6%, respectively. HS prevalence has significantly increased among PBC patients since 2010 (APC: +37.4%). While concomitant HS was associated with a higher risk of hepatic decompensation (OR: 1.6, 95% CI: 1.3-2.1, I2=0%) and hepatocellular carcinoma (OR: 1.8, 95% CI: 1.3-2.6, I2=0%) in patients with AIH, HS did not influence the clinical outcomes in patients with PBC. Treatment response in AIH and PBC was not influenced by concomitant HS. Available data on PSC with concomitant HS were insufficient to assess its association with clinical outcomes. CONCLUSIONS: AIH patients with concomitant HS had worse outcomes than those without HS; whereas HS did not influence the clinical outcomes in patients with PBC. Future research evaluating the impact of HS on PSC and overlap syndrome is much needed.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prevalence and clinical impact of hepatic steatosis on autoimmune liver disease: A systematic review and meta-analysis
- Date Crossref
- 24/04/2026
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National University of Singapore pays non établi dans la noticeUniversité ou école supérieure
-
University of Alberta Division of Gastroenterology and Hepatology pays non établi dans la noticeUniversité ou école supérieure
-
National University Hospital Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
Changi General Hospital Department of Gastroenterology and Hepatology pays non établi dans la noticeÉtablissement de santé
-
Duke-NUS Medical School pays non établi dans la noticeUniversité ou école supérieure
-
Yong Loo Lin School of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Duke–NUS Medical School pays non établi dans la noticeInstitution
National University of Singapore, Division of Gastroenterology and Hepatology — University of Alberta et Department of Medicine — National University Hospital, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.